Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia

Context Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome usually caused by oversecretion of fibroblast growth factor 23 (FGF23) from a phosphaturic mesenchymal tumor (PMT). PMTs are usually benign neoplasms but some of them show malignant characteristics.Objective The aim of this study was to compare the clinical characteristics of benign and malignant PMTs inducing TIO.Methods On March 31, 2023, we performed a systematic review of individual patient data analysis in Medline, Google Scholar, Google book, and Cochrane Library using the terms tumor induced osteomalacia, oncogenic osteomalacia, hypophosphatemia, with no language restrictions and according to Preferred Reporting Items for Systematic reviews and Meta-Analyses criteria.Results Overall, we collected data from 837 patients with TIO in which the diagnosis of benign and malignant PMT was specified. Of them, 89 were affected by malignant PMT and 748 by benign PMT. Patients with malignant PMTs were younger and presented bone pain, functional impairment, and bone deformities more frequently. Malignant PMTs showed higher values of intact FGF23 and a higher mortality rate.Conclusion The study results identify the clinical characteristics of patients with malignant TIO, permitting the early identification of patients with PMT at increased risk of malignancy. This may significantly improve the diagnostic approach to disease. Further experimental studies are mandatory to clarify the role of FGF23 in the pathogenesis of malignancy in PMTs.

Automated summary

This study compares the clinical characteristics of benign and malignant PMTs inducing TIO. It finds that patients with malignant PMTs are younger and more likely to experience bone pain, functional impairment, and bone deformities. Malignant PMTs also have higher levels of intact FGF23 and a higher mortality rate.